Shanghai MicroPort MedBot (Group) Co., Ltd. announced that iSR'obot Mona Lisa Robotic Transperineal Prostate Biopsy System, a product of Shanghai Intbot Robotics Co., Ltd., a joint venture company in China jointly established by the Company and Biobot Surgical Pte. Ltd., has completed enrollment for the registrational clinical trials. Nanjing Drum Tower Hospital (the Affiliated Hospital of Nanjing University Medical School) led the clinical trial, with the participation of The First Affiliated Hospital of Xi'an Jiaotong University and Northern Jiangsu People's Hospital.

Mona Lisa operated stably and safely and processed smoothly during the surgeries, with obvious advantages in terms of safety of surgeries, learning curves and the detection rate of punctures as compared with manual punctures in traditional surgeries, which is proved to have significant clinical value. With the completion of this clinical enrollment, Mona Lisa has become the first prostate puncture robot completing enrollment for registrational clinical trials in the field of urology in China, while it is also a new breakthrough of the Company in the field of percutaneous puncture, indicating a major step for the accurate diagnosis of prostate cancer. Shanghai Intbot plans to submit the registration application of Mona Lisa to the National Medical Products Administration in the third quarter of 2022.